Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Top 20 Style Brands for Pioneers06.07.2023 - 2US FDA declines to approve Corcept's drug for rare hormonal disorder01.01.2026
- 3IDF uncovers 7 km.-long Gaza terror tunnel where Hamas held Hadar Goldin20.11.2025
- 4They died 'doing what they loved': The stories of workers in their 80s who died on the job28.11.2025
- 5FDA proposes use of sunscreen ingredient popular in other countries11.12.2025
- Study finds humans were making fire 400,000 years ago, far earlier than once thought
- Figure out how to Consolidate All encompassing Practices with a Degree in Brain research
- Focus on Yourself: Wellbeing and Taking care of oneself Practices
- Palestinians reel under winter rains as Israel blocks Gaza shelter supplies
- Manual for extravagance SUVs for seniors
- 6 Nations for Setting up camp
- Modern surgery began with saws and iron hands – how amputation transformed the body in the Renaissance
- Misinterpretations and Mistakes Portrayed by Hollywood in the General set of laws
- Israel faces tough choices over haredi draft exemptions, legal expert warns
